Undisclosed SNAP-CAR T therapy / Coeptis, University of Pittsburgh - LARVOL DELTA

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award (PRNewswire) - "Coeptis Therapeutics Holdings, Inc...is pleased to acknowledge and congratulate Professor Alexander Deiters, on receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award. This prestigious award honors outstanding individuals whose scholarly commitments and contributions to research have significantly advanced their respective fields. Deiters co-developed a CAR T cell therapy platform called 'SNAP-CAR' that is based on covalent modification of a universal receptor with adaptor molecules that target these T cells to tumors."

Preclinical • Hematological Malignancies • Immunology • Oncology • Solid Tumor

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (PRNewswire) - "Coeptis Therapeutics Holdings, Inc...today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T Cells, a 'universal' CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, and a recent amendment to the agreement for SNAP-CAR NK, an allogeneic natural killer (NK) cell therapy platform....'We remain committed to developing these remarkable technologies as treatments for various indications across oncology where there is immense unmet need.'"

Licensing / partnership • Hematological Malignancies • Immunology • Oncology • Solid Tumor

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 (PRNewswire) - "Coeptis Therapeutics Holdings...announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, through combinatorial use of different adaptors will be the subject of a poster presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)....The poster presentation...describes research involving SNAP-CAR, a 'universal' CAR T cell therapy platform, that demonstrates the technology's versatile antigen targeting abilities both in vitro and in vivo in human tumor xenograft models. In vitro experiments showed potent and specific SNAP-CAR function with co-administered adaptors targeting HER2, EGFR, and CD20 on cancer cell lines including activation of CD69 and CD107a markers, specific target cell lysis, and IFN-gamma production."

Preclinical • Oncology

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology (PRNewswire) - "Coeptis Therapeutics Holdings, Inc...announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Cell, a 'universal' CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer."

Licensing / partnership • Hematological Malignancies • Oncology • Solid Tumor

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (PRNewswire) - "Coeptis Therapeutics Holdings, Inc.. announced that an abstract involving SNAP-CAR has been accepted for presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023). SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego. The poster presentation...will detail research involving SNAP-CAR, a 'universal' CAR T cell therapy platform that can be adapted to different cancer indications. Licensed by Coeptis from the University of Pittsburgh, SNAP-CAR offers an opportunity to direct the power of CAR T to an array of cancers that have, until now, been inaccessible via current cell therapy technologies by providing a highly programmable antigen targeting platform."

Preclinical • Oncology

Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program (PRNewswire) - "Coeptis Therapeutics Holdings, Inc...announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology....Under the terms of the sponsor research agreement, the University of Pittsburgh will conduct pre-clinical research on the SNAP-CAR technology necessary to enable the filing of an Investigational New Drug (IND) application for clinical trials involving SNAP-CAR T cells targeting HER2-positive cancers."

Licensing / partnership • Breast Cancer • Gynecologic Cancers • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program (PRNewswire) - "Coeptis Therapeutics Holdings, Inc...today announced an agreement with IQVIA, a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, to support the development of SNAP-CAR, a multi-antigen chimeric antigen receptor T cell (CAR T) technology that Coeptis licensed from the University of Pittsburgh. SNAP-CAR is designed as a 'universal' CAR T cell therapy platform that can be adapted to different cancer indications, including hematologic and solid tumors. Under the terms of the agreement, IQVIA will collaborate with Coeptis to prioritize the target indications for the SNAP-CAR program and manage activities designed to enable the filing of an Investigational New Drug (IND) application."

Licensing / partnership • Hematological Malignancies • Oncology • Solid Tumor